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The 2014/15 influenza season in the United Kingdom 
(UK) was characterised by circulation of predomi-
nantly antigenically and genetically drifted influenza 
A(H3N2) and B viruses. A universal paediatric influ-
enza vaccination programme using a quadrivalent live 
attenuated influenza vaccine (LAIV) has recently been 
introduced in the UK. This study aims to measure the 
end-of-season influenza vaccine effectiveness (VE), 
including for LAIV, using the test negative case–con-
trol design. The overall adjusted VE against all influ-
enza was 34.3% (95% confidence interval (CI) 17.8 to 
47.5); for A(H3N2) 29.3% (95% CI: 8.6 to 45.3) and for 
B 46.3% (95% CI: 13.9 to 66.5). For those aged under 
18 years, influenza A(H3N2) LAIV VE was 35% (95% CI: 
−29.9 to 67.5), whereas for influenza B the LAIV VE was 
100% (95% CI:17.0 to 100.0). Although the VE against 
influenza A(H3N2) infection was low, there was still 
evidence of significant protection, together with mod-
erate, significant protection against drifted circulat-
ing influenza B viruses. LAIV provided non-significant 
positive protection against influenza A, with signifi-
cant protection against B. Further work to assess the 
population impact of the vaccine programme across 
the UK is underway.
Introduction
The United Kingdom (UK) has a longstanding selective 
influenza vaccination programme targeting individu-
als at an increased risk of developing severe disease 
following infection. This has been undertaken with a 
wide range of inactivated influenza vaccines that are 
available on the UK market. In 2013/14, the phased 
roll-out of a universal childhood influenza vaccination 
programme with a newly licensed live attenuated influ-
enza vaccine (LAIV) commenced. In 2014/15, all two, 
three and four year olds, children of school age (see 
below for details across the countries of the UK) and 
children aged from six months to 18 years of age in a 
clinical risk group, who did not have any contraindica-
tions to receive LAIV, were offered a quadrivalent LAIV. 
Influenza vaccine is offered to those groups older than 
six months of age with underlying clinical disease such 
as chronic heart or respiratory disease that put the 
patient at increased risk of serious illness from influ-
enza or where influenza may exacerbate the underlying 
disease itself. For healthy school age children, differ-
ent parts of the UK targeted different groups [1]: all 
primary school age children in Scotland and Northern 
Ireland; primary school and secondary school age chil-
dren (11–13 years) in pilot areas in England and children 
aged 11–12 years in Wales. Adults in a target group are 
offered one of the inactivated vaccines available in the 
UK. In February 2014, northern hemisphere 2014/15 
influenza vaccines were recommended by the World 
Health Organization (WHO) to contain the following 
components: an A/California/7/2009 (H1N1)pdm09-
like virus; an A/Texas/50/2012 (H3N2)-like virus and 
a B/Massachusetts/2/2012-like B/Yamagata-lineage 
virus, plus a B/Brisbane/60/2008-like B/Victoria-
lineage virus for quadrivalent vaccines [2].
Moderate levels of influenza activity circulated in 
the community in the UK in 2014/15, with influenza 
A(H3N2) the dominant strain for the majority of the 
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season from December 2014, and influenza B from 
February to April 2015 [3]. The community impact of 
influenza A(H3N2) virus was predominantly seen in the 
elderly, with numerous outbreaks in care homes [3]. 
Admissions to hospital and intensive care units (ICU) 
were also observed though with some evidence of vari-
ation across the UK, with peak ICU numbers higher in 
England than in recent seasons and levels of excess 
mortality, particularly in the elderly, higher in England 
than the influenza season of 2008/09 when A(H3N2) 
was also the dominant subtype [3].
As in many northern hemisphere countries, the 
2014/15 season was characterised by the emergence 
of A(H3N2) strains that were antigenically and geneti-
cally drifted from the 2014/15 H3N2 vaccine strain, 
A/Texas/50/2012 and more closely related to the A/
Switzerland/9715293/2013 virus, the vaccine strain 
recommended for the forthcoming 2015/16 season [4]. 
Indeed, an interim mid-season UK estimate of sea-
sonal influenza vaccine effectiveness (VE) calculated 
in January 2015 showed a low effectiveness of 3.4% 
(95% CI: −44.8 to 35.5) against laboratory-confirmed 
influenza infection in primary care [5]. Later in the 
season, influenza B viruses circulated, with the major-
ity antigenically and genetically distinguishable from 
the northern hemisphere 2014/15 B/Yamagata-lineage 
vaccine strain [3].
This study reports the final end-of-season VE findings 
for the 2014/15 seasonal influenza vaccine in prevent-
ing medically attended laboratory confirmed influenza 
A(H3N2) and B using the established primary care sen-
tinel swabbing surveillance schemes across the UK by 
sub-type and age group [5,6]. In addition, the study 
examines the potential protective effect of vaccination 
of children (< 18 years of age) using the newly licensed 
intranasally administered LAIV compared with the 
inactivated, injectable influenza vaccines, in a season 
when drifted strains circulated.
Methods
Study population and period
Data were obtained from five primary care influ-
enza sentinel swabbing surveillance schemes in the 
UK from England (two schemes), Scotland, Wales 
and Northern Ireland. Details of the Royal College of 
Table 1
Details of influenza A(H3N2) haemagglutinin sequences obtained from GISAID used in the phylogenetic analysis 
Virus isolate
Segment ID/
Accession 
number
Country
Collection 
date (year-
month-day)
Originating laboratory Submitting laboratory
A/Hong Kong/5738/2014 EPI539806 China 2014-04-30
Government Virus Unit, 
Hong Kong (SAR)
National Institute for Medical 
Research, London, UK
A/Switzerland/9715293/2013 EPI530687 Switzerland 2013-12-06
Hopital Cantonal 
Universitaire de Geneves, 
Switzerland
National Institute for Medical 
Research, London, UK
A/Samara/73/2013 EPI460558
Russian 
Federation
2013-03-12
WHO National Influenza 
Centre, Saint Petersburg, 
Russian Federation
National Institute for Medical 
Research, London, UK
A/Texas/50/2012 EPI391247 United States 2012-04-15
Texas Department of 
State Health Services, 
Austin, USA
Centers for Disease Control 
and Prevention, Atlanta, USA
A/AthensGR/112/2012 EPI358885 Greece 2012-02-01
Hellenic Pasteur Institute, 
Athens, Greece
National Institute for Medical 
Research, London, UK
A/Stockholm/18/2011 EPI326139 Sweden 2011-03-28
Swedish Institute for 
Infectious Disease 
Control, Solna, Sweden
National Institute for Medical 
Research, London, UK
A/Perth/16/2009 EPI211334
Australia/ 
Western 
Australia
2009 (month 
and day 
unknown)
WHO Collaborating 
Centre for Reference and 
Research on Influenza, 
Melbourne, Australia
Centers for Disease Control 
and Prevention, Atlanta, USA
A/Glasgow/400003/2015 EPI175027
United 
Kingdom
2015-01-02
Gart Naval General 
Hospital, Glasgow, UK
National Institute for Medical 
Research, London, UK
A/Glasgow/400097/2015 EPI175028 2015-01-02
A/Glasgow/400580/2014 EPI175029 2014-12-26
A/Glasgow/401673/2014 EPI175030 2014-12-29
A/Glasgow/401674/2015 EPI175031 2015-01-01
A/Glasgow/401678/2015 EPI175032 2015-01-07
A/Glasgow/431929/2014 EPI175077 2014-11-23
GISAID: Global Initiative on Sharing All Influenza Data; UK: United Kingdom; USA: United States of America; WHO: World Health Organization.
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General Practitioners (RCGP), Public Health England 
(PHE) Specialist Microbiology Network (SMN), Public 
Health Wales, Public Health Agency (PHA) of Northern 
Ireland and Health Protection Scotland (HPS) swabbing 
schemes have been published previously [6].
The study period ran from 1 October 2014 to 17 April 
2015. A convenience sample of patients presenting with 
an influenza-like illness (ILI) were swabbed as part of 
clinical care, after having given verbal consent. Cases 
were defined as persons presenting during the study 
period in a participating General Practitioner (GP) prac-
tice with an ILI, who were swabbed and then tested 
positive for influenza A or B. ILI was clinically defined 
as an individual presenting in primary care with an 
acute respiratory illness with physician-diagnosed 
fever or complaint of feverishness in the previous 
seven days. Controls were individuals presenting with 
ILI in the same period that were swabbed and tested 
negative for influenza.
A standardised questionnaire was completed by the 
GP while swabbing the patient during the consultation. 
Demographic, clinical and epidemiological information 
was collected from cases and controls, including date 
of birth, sex, defined underlying clinical risk group, 
date of onset of respiratory illness, date of specimen 
collection, and influenza vaccination status for the 
2014/15 season with vaccination dates. Information 
was collected on whether the vaccine was adminis-
tered by injection or intranasally, with injection a proxy 
for inactivated influenza vaccine (IIV) and intranasal 
administration, a proxy for LAIV.
Laboratory methods
Samples in England were sent to the PHE Microbiology 
Services, Colindale (RCGP scheme) or one of the spe-
cialist PHE microbiology laboratories (SMN scheme). 
Samples in Northern Ireland were sent to the Regional 
Virus Laboratory, Belfast, in Scotland to the West of 
Scotland Specialist Virology Centre, Glasgow (HPS 
scheme), and in Wales to the Public Health Wales 
Specialist Virology Centre, Cardiff. All these laborato-
ries participate in the UK Influenza Testing Laboratory 
Network and undertake testing annually of PHE molec-
ular influenza detection external quality assurance 
scheme panels [7]. Laboratory confirmation of study 
samples was undertaken using comparable methods 
with real-time PCR (RT-PCR) assays capable of detect-
ing circulating influenza A and influenza B viruses and 
other respiratory viruses [8,9]. Further strain character-
isation was also performed; influenza viruses were iso-
lated in MDCK or MDCK-SIAT1 cells from RT-PCR positive 
samples from England as previously described [10,11]. 
Influenza virus isolates with a haemagglutination 
titre ≥ 40 were characterised antigenically using post-
infection ferret antisera in haemagglutination inhibi-
tion (HI) assays, with guinea pig or turkey red blood 
cells [12].
Nucleotide sequencing of the haemagglutinin (HA) 
gene of a subset of influenza A(H3N2) viruses with H3 
subtype PCR detection cycle threshold (Ct) values ≤ 32, 
was undertaken. The samples selected were represent-
ative of vaccination status, date of sample collection, 
geographical location and antigenic characterisation 
(when available) across the study period. Sequencing 
was performed using an influenza A full genome ampli-
fication protocol [13] for sequencing on an Illumina 
MiSeq sequencer.
A phylogenetic tree was constructed with a neighbour-
joining algorithm available in the Mega 6 software 
(http://www.megasoftware.net) [10]. HA sequences 
from reference strains used in the phylogenetic anal-
ysis were obtained from the EpiFlu database of the 
Global Initiative on Sharing Avian Influenza Data 
(GISAID) (Table 1). 
Figure 1
Swabbing results of ILI patients in primary care in the 
United Kingdom, October 2014 to April 2015 (n=4,442)
Samples in original dataset
N=4,442
Excluded samples sequentially:
Date of sample prior to 1 Oct 2014 (n=102)
Inﬂuenza status unknown (n=12)
LAIV strain (n=5)
Vaccination status unknown (n=116)
Vaccination within 14 days from onset (n=77)
Date of onset unknown (n=277)
Swab more than 7 days after onset (n=922)
Samples included 
in the analysis
n=2,931
Cases
n=902 
Controls
n=2,029 
ILI: influenza-like illness; LAIV: live attenuated influenza vaccine.
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Table 2
Details for influenza A and B cases (n=902) and controls (n=2,029), United Kingdom, October 2014 to April 2015
Controls 
(n = 2,029)
B 
(n = 184)
A(H1N1) 
(n = 60)
A(H3N2) 
(n = 629)
A (untyped) 
(n = 31) P valuea
n (%) n (%) n (%) n (%) n (%)
Age group (years) 0.062
< 18 507 (72.3) 33 (4.7) 16 (2.3) 142 (20.3) 4 (0.6)
18–44 770 (69.1) 60 (5.4) 27 (2.4) 244 (21.9) 16 (1.4)
45–64 502 (66.1) 79 (10.4) 16 (2.1) 157 (20.7) 6 (0.8)
≥ 65 250 (71) 12 (3.4) 1 (0.3) 84 (23.9) 5 (1.4)
Missing information 0 (0) 0 (0) 0 (0) 2 (100) 0 (0)
Sex 0.077
Female 1,198 (70.6) 101 (5.9) 34 (2) 352 (20.7) 14 (0.8)
Male 822 (67.5) 83 (6.8) 26 (2.1) 271 (22.2) 17 (1.4)
Missing 9 (60) 0 (0) 0 (0) 6 (40) 0 (0)
Surveillance scheme < 0.001
Northern Ireland 67 (55.4) 9 (7.4) 2 (1.7) 28 (23.1) 15 (12.4)
RCGP 832 (65.5) 100 (7.9) 40 (3.1) 300 (23.6) 0 (0)
SMN 235 (75.1) 15 (4.8) 3 (1) 54 (17.3) 6 (1.9)
Scotland 867 (74) 60 (5.1) 15 (1.3) 221 (18.9) 10 (0.9)
Wales 28 (51.9) 0 (0) 0 (0) 26 (48.1) 0 (0)
Risk groupb 0.473
No 1,376 (68.7) 149 (7.4) 48 (2.4) 416 (20.8) 17 (0.8)
Yes 479 (70.1) 28 (4.1) 6 (0.9) 158 (23.1) 12 (1.8)
Missing 174 (71.3) 7 (2.9) 6 (2.5) 55 (22.5) 2 (0.8)
Interval onset-swab (days) < 0.001
0–1 275 (67.1) 22 (5.4) 9 (2.2) 100 (24.4) 4 (1)
2–4 975 (64.4) 108 (7.1) 34 (2.2) 380 (25.1) 20 (1.3)
5–7 779 (77.4) 54 (5.4) 17 (1.7) 149 (14.8) 7 (0.7)
Month < 0.001
October 222 (94.9) 2 (0.9) 2 (0.9) 7 (3) 1 (0.4)
November 354 (94.4) 6 (1.6) 0 (0) 15 (4) 0 (0)
December 417 (65.1) 4 (0.6) 6 (0.9) 209 (32.6) 5 (0.8)
January 476 (61.7) 20 (2.6) 19 (2.5) 251 (32.5) 7 (0.9)
February 311 (59.7) 51 (9.8) 17 (3.3) 128 (24.6) 14 (2.7)
March 198 (64.1) 77 (24.9) 14 (4.5) 17 (5.5) 4 (1.3)
April 51 (64.6) 24 (30.4) 2 (2.5) 2 (2.5) 0 (0)
Vaccination status 0.104
Unvaccinated 1,507 (68.5) 151 (6.9) 53 (2.4) 469 (21.3) 21 (1)
Vaccinated (14–91 days ago) 293 (73.8) 6 (1.5) 1 (0.3) 93 (23.4) 4 (1)
Vaccinated(> 91 days ago) 229 (68.4) 27 (8.1) 6 (1.8) 67 (20) 6 (1.8)
Pilot area 0.002
No 725 (65.8) 91 (8.3) 28 (2.5) 253 (23) 6 (0.5)
Yes 1,272(71.2) 91 (5.1) 32 (1.8) 368 (20.6) 25 (1.4)
Missing 32(76.2) 2 (4.8) 0 (0) 8 (19) 0 (0)
Vaccine administration method (under 18 only) 0.022
Injection 11 (55) 2 (10) 0 (0) 6 (30) 1 (5)
Intranasal 66 (80.5) 0 (0) 3 (3.7) 13 (15.9) 0 (0)
Missing 5 (62.5) 1 (12.5) 0 (0) 2 (25) 0 (0)
RCGP: Royal College of General Practitioners; SMN: Specialist Microbiology Network.
Two people were positive for both influenza B and influenza A (one H1N1, one H3N2).
a Positive versus negative for influenza.
b Individuals older than six months of age with underlying clinical disease such as chronic heart or respiratory disease that put the patient at 
increased risk of serious illness from influenza or where influenza may exacerbate the underlying disease itself.
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Figure 2
Phylogenetic analysis of representative haemagglutinin sequences from United Kingdom influenza A(H3N2) 2014/15 viruses 
with reference viruses obtained from the GISAID EpiFlu database 
 A/England/50300025/2015   
 A/Glasgow/401673/2014 
 A/Glasgow/401674/2015 
 A/England/50300033/2015 
 A/England/50740161/2015   
 A/England/12/2015 
 A/England/72/2015 
 A/England/50260151/2015   
 A/England/50360024/2015 
 A/England/50220079/2015   
 A/England/50280058/2015   
 A/England/50320276/2015 
 A/England/50380052/2015 
 A/England/50300008/2015   
 A/England/50360038/2015 
 A/Glasgow/431929/2014 
 A/England/50200164/2015   
 A/England/50360027/2015   
 A/England/49/2015 
 A/England/50220082/2015 
 A/England/50800025/2015   
 A/England/50400282/2015 
 A/England/50660076/2015   
 A/England/50220068/2015 
 A/England/50400284/2015   
 A/England/50260150/2015   
 A/England/50740149/2015   
 A/England/11/2015  
 A/Glasgow/400003/2015 
 A/England/50280041/2015 
 A/England/50520248/2015   
 A/England/50780065/2015   
 A/Glasgow/400097/2015 
 A/England/50/2015   
 A/England/114/2015   
 A/England/50200187/2015 
 A/England/599/2014 
 A/England/50300044/2015   
 A/Glasgow/400580/2014 
 A/Hong_Kong /5738/2014  (3C.2a)  
 A/England/50240248/2015   
 A/England/591/2014 
 A/England/13/2015 
 A/Glasgow/401678/2015 
 A/Switzerland/9715293/2013  (3C.3a)  
 A/England/60/2015 
 A/England/169/2015   
 A/Samara/73/2013  (3C.3)  
 A/England/513/2014 
 A/England/57/2015 
 A/England/87/2015   
 A/England/50280054/2015 
 A/England/127/2015   
 A/England/166/2015   
 A/England/516/2014 
 A/England/18/2015   
 A/England/112/2015   
 A/England/105/2015   
 A/England/10/2015   
 A/England/113/2015   
 A/England/32/2015 
 A/England/50400278/2015 
 A/Texas/50/2012  (3C.1)  
 A/AthensGR /112/2012  (3B)  
 A/Stockholm/18/2011  (3A)  
 A/Perth/16/2009 
0.002 
vaccine virus  
clade reference viruses  
 vaccinated 
3c.2a  
3c.3a  
3C.3  
L3I  
N144S( -CHO)  
F159Y  
K160T(+CHO)  
N225D  
Q311H  
D489N  
N145S  
A138S  
F159S  
N225D  
T128A( -CHO)  
R142G  
Q33R  
S45N(+CHO)  
T48I  
N278K  
Y94H  
L157S  
V347K  
E62K  
N122D( -CHO)  
K83R  
K261Q  Q197H  
Branch lengths are drawn to scale. Amino acid changes characteristic of genetic clades/subclades are marked on the tree.
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The England HA sequences obtained in this study, 
which were also used in the phylogenetic analy-
sis, were deposited in GISAID under the following 
accession numbers: EPI607577, EPI607585, EPI607593, 
EPI607601, EPI607609, EPI607617, EPI607625, EPI607633, 
EPI607641, EPI607649, EPI607657, EPI607665, EPI607673, 
EPI607681, EPI607689, EPI607697, EPI607705, EPI607713, 
EPI607721, EPI607729, EPI607737, EPI607745, EPI607753, 
EPI607761, EPI607769, EPI607777, EPI607785, EPI607793, 
EPI607801, EPI607809, EPI607817, EPI607825, EPI607833, 
EPI607841, EPI607849, EPI607857, EPI607865, EPI607873, 
EPI607881, EPI607889, EPI607899, EPI607914, EPI607930, 
EPI607945, EPI607960, EPI607975, EPI607990, EPI608006, 
EPI608022EPI608038, EPI608051, EPI608067.
Statistical methods
Persons were defined as vaccinated if the date of vacci-
nation with the 2014/15 influenza vaccine (either inac-
tivated or live attenuated) was 14 or more days before 
onset of illness. To take into account the time taken 
for an immune response, those in whom the period 
between vaccination and onset of illness was less than 
14 days, were excluded from the analysis. Those with a 
missing date of onset or an onset date more than seven 
days before the swab was taken, were excluded.
VE was estimated by the test–negative case–con-
trol (TNCC) design. In this design, VE is calculated as 
1-(odds ratio, OR) obtained using multivariable logis-
tic regression models with influenza A and B RT-PCR 
results as outcomes, and seasonal vaccination status 
as the linear predictor. No analysis was conducted for 
influenza A(H1N1)pdm09 because of the small number 
of cases. In the analyses evaluating VE for a specific 
type or subtype, those positive for other types/sub-
types were excluded. Age (coded into four standard age 
groups, < 18, 18–44, 45–64 and ≥ 65 years), sex, clinical 
risk group, surveillance scheme (RCGP, SMN, Scotland, 
Wales, Northern Ireland), pilot area and date of sam-
ple collection (month) were investigated as potential 
confounding variables. Pilot area was defined as those 
parts of the UK where primary school-age vaccination 
was undertaken (England primary pilot areas, Scotland 
and Northern Ireland - all primary school age children). 
To investigate whether the VE changed in relation 
to time since vaccination, analyses stratifying VE by 
time since vaccination (less than three months, three 
months or longer) and by period (October to January, 
February to April) were undertaken. Where date of vac-
cination was not given, time since vaccination was 
estimated based on the assumption that vaccination 
occurred at the median vaccination date of 15 October 
2014, and also treated as missing in a sensitivity analy-
sis. VE was also assessed stratified by age group and 
scheme with differences in VE assessed by a likelihood 
ratio test between groups where numbers were not 
too low for a precise estimate. In addition, an analysis 
was performed just in those aged ≥18 years (in whom 
IIV would have been given). Finally, to estimate the 
VE for LAIV, an estimate was obtained in those aged 
under 18 years as well as for two, three and four year 
olds who had received the intranasal vaccine. A sensi-
tivity analysis was undertaken to include all samples 
dropped from the main analysis due to late sampling 
(more than seven days after onset). A regression analy-
sis was undertaken to compare the viral load using the 
Ct values for H3 detection by PCR in vaccinated and 
unvaccinated A(H3N2) laboratory-confirmed cases in 
samples from the RCGP scheme in England.
All statistical analyses were carried out in Stata version 
13 (StataCorp, College Station, Texas).
Results
A total of 4,442 individuals were swabbed in primary 
care during the study period. For the VE analysis, 116 
were excluded due to missing vaccination status, 277 
due to missing date of onset, 922 because they were 
swabbed more than seven days after onset, 77 because 
they were vaccinated within 14 days of onset and five 
because of vaccine (LAIV) contamination of samples 
(Figure 1).
Cases (n=902) Controls (n=2,029)
Crude VE 
(95% CI)
Adjusteda VE 
(95% CI)
Vaccinated Unvaccinated Vaccinated Unvaccinated
Influenza A or B 210 692 522 1,507
12.4% 
(−5.3 to 27.1)
34.3% 
(17.8 to 47.5)
Influenza A 177 543 522 1,507
5.9% 
(−14.6 to 22.7)
29.9% 
(10.5 to 45.1)
Influenza A/H3 160 469 522 1,507
1.5% 
(−20.9 to 19.8)
29.3% 
(8.6 to 45.3)
Influenza B 33 151 522 1,507
36.9% 
(6.9 to 57.3)
46.3% 
(13.9 to 66.5)
CI: confidence interval; VE: vaccine effectiveness.
a Adjusted for age group, sex, month, pilot area and surveillance scheme.
Table 3
Samples positive (cases, n = 902) and negative (controls, n = 2,029) for influenza A and B according to vaccination status and 
VE estimates, United Kingdom, October 2014 to April 2015
7www.eurosurveillance.org
The details of those remaining in the study (n=2,931) 
are given in Table 2 according to the swab result. 
Positivity rates differed significantly by surveillance 
scheme, interval from onset and pilot area.
Strain characterisation
During the 2014/15 season, the PHE Respiratory Virus 
Unit (RVU) isolated and antigenically characterised 84 
A(H3N2) influenza viruses received through the two 
primary care influenza sentinel swabbing surveillance 
schemes in England. The majority were antigenically sim-
ilar to the A/Texas/50/2012 H3N2 northern hemisphere 
2014/15 vaccine strain, however 26 showed reduced 
reactivity in antigenic tests with A/Texas/50/2012 anti-
serum. These 26 isolates were antigenically similar to 
A/Switzerland/9715293/2013, the H3N2 virus selected 
for the 2015/16 northern hemisphere influenza vac-
cine [2]. A/Switzerland/9715293/2013 is related to, but 
antigenically and genetically distinguishable, from the 
A/Texas/50/2012 vaccine virus. One virus isolate was 
antigenically similar to A/England/507/2014, a refer-
ence virus from the 3C.2a genetic clade.
Genetic characterisation of A(H3N2) viruses was per-
formed by both RVU and the West of Scotland labo-
ratory. Of 118 A(H3N2) viruses from samples received 
through the RCGP scheme in England and characterised 
genetically by RVU, some of which did not grow suffi-
ciently to be able to be antigenically characterised, and 
149 A(H3N2) viruses genetically characterised by the 
West of Scotland laboratory, the majority (192; 72%) 
fall into the haemagglutinin (HA) genetic subgroup 
3C.2a and 7 (3%) fall into another HA subgroup, 3C.3a; 
viruses from both of these HA genetic subgroups have 
been shown to be antigenically distinguishable from 
the 2014/15 A(H3N2) vaccine virus [4]. The remaining 
68 (25%) H3N2 viruses sequenced had HA genes which 
belong in genetic group 3C.3, which is antigenically 
similar to the 2014/15 A(H3N2) vaccine virus.
Of 45 influenza B viruses isolated and antigenically 
characterised as belonging to the B/Yamagata/16/88 
lineage by RVU, 41 showed reduced reactivity in anti-
genic tests (≥ four-fold difference) with antiserum 
to the 2014/15 northern hemisphere B/Yamagata-
lineage trivalent and quadrivalent vaccine virus, B/
Massachusetts/2/2012, with 29 of these 41 isolates 
showing significant (> four-fold difference) reduced 
reactivity, indicative of antigenic drift. These 41 iso-
lates were antigenically similar to B/Phuket/3073/2013, 
the influenza B/Yamagata lineage virus selected 
for 2015/16 northern hemisphere influenza vac-
cines. B/Phuket/3073/2013 is related to, but anti-
genically and genetically distinguishable, from the B/
Massachusetts/2/2012 vaccine virus. Three influenza 
B viruses have been isolated and antigenically char-
acterised as belonging to the B/Victoria/2/87 lineage, 
similar to the influenza B/Victoria-lineage component 
Table 4
Adjusted vaccine effectiveness estimates for influenza by age, surveillance scheme, LAIV pilot area and by risk group in > 18 
year olds, United Kingdom, October 2014 to April 2015 (n = 2,228)
Factor Level Adjusted VEa % (95% CI) by type
A A(H3N2) B
Age (years) 
> 18 30.4 (8.4 to 47.2) 29.4(5.8 to 47.1) 43.6(5.5 to 66.3),
18–44 34.5 (−3.0 to 58.4) 30.3 (−12.4 to 56.7) 40.4 (−50.9 to 76.5)
45–64 32.4 (−1.8 to 55.2) 31.1 (−5.8 to 55.2) 49.2 (−0.4 to 74.3)
≥ 65 30.2 (−46.4 to 66.7) 32.6 (−44.5 to 68.6) −203 (−2,300 to 61.7)b
18–64 33.4 (10.5 to 50.5) 31.2 (6.1 to 49.6) 41.9 (0.1 to 66.1)
Scheme 
RCGP 41.5 (19.9 to 57.3) 37.7 (13.5 to 55.1) 24.4 (−30.2 to 56.1)
SMN −13 (−152.6 to 49.4) −23.6 (−192.2 to 47.2) 66.2 (−79.4 to 93.6)
Scotland 23.1 (−9.4 to 46) 19.2 (−16.2 to 43.8) 81.5 (47.2 to 93.5)
Wales −41 (−458.6 to 64.4) −41 (−458.6 to 64.4) No influenza B
Northern Ireland 21.7 (−150.3 to 75.5) 44.5 (−122.6 to 86.2) −18.7 (−539.4 to 78)b
Pilot area 
Non-pilot 33.9 (1.5 to 55.7) 32.5 (−2.9 to 55.7) 34.2 (−28.4 to 66.3)
Pilot 25.4 (−2.3 to 45.6) 24.5 (−5.3 to 45.8) 57.4 (13.8 to 78.9)
Risk groupc 
≥ 65 or in a risk group 34.8 (3.1 to 56.2) 32.4 (−2.4 to 55.3) 15.5 (−107.6 to 65.6)
In a risk group 32.5 (−3.4 to 55.9) 30.0 (−9.3 to 55.2) 40.6 (−55.6 to 77.3)
CI: confidence interval; RCGP: Royal College of General Practitioners Research and Surveillance Centre; SMN: Specialist Microbiology 
Network; VE: vaccine effectiveness.
a Adjusted for age group, sex, month, pilot area and surveillance scheme.
b Unadjusted 95% confidence interval.
c Individuals older than six months of age with underlying clinical disease such as chronic heart or respiratory disease that put the patient at 
increased risk of serious illness from influenza or where influenza may exacerbate the underlying disease itself.
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(B/Brisbane/60/2008) of the 2014/15 northern hemi-
sphere quadrivalent vaccine. The West of Scotland 
laboratory genetically characterised 184 influenza B 
viruses by real-time PCR; 171 (93%) fell within the B/
Yamagata lineage and 13 (7%) within the B/Victoria 
lineage. Of these, 37 B/Yamagata lineage viruses were 
sequenced and all genetically characterised as B/
Phuket/3073/2013-like, which is antigenically distin-
guishable from the B/Yamagata vaccine virus. Four B/
Victoria lineage viruses were genetically characterised 
as B/Brisbane/60/2008-like, which matches the B/
Victoria lineage component of the quadrivalent vaccine.
Figure 2 shows the phylogenetic characteristics of the 
HA of circulating A(H3N2) strains.
Model fitting for vaccine effectiveness 
estimation
When estimating vaccine effects, age group, sex, time-
period (defined by month of sample collection), pilot 
area and surveillance scheme were adjusted for in a 
multivariable logistic regression model. Although all 
these variables were significantly associated with hav-
ing a positive swab, only age group and time-period 
were confounders for the vaccine effects (changed 
the estimate by more than 5% as previously described 
[5,6]). Information on risk group was missing for 244 of 
2,931 samples (8.3%) and was therefore not included 
in the final model. If risk group was included, it was 
found not to be associated with being positive and the 
VE estimates remained similar.
Tables 3, 4 and 5 show vaccine effectiveness estimates 
against influenza A (overall), A(H3N2) and B in all 
ages, ≥ 18 year olds and < 18 year olds. The overall influ-
enza VE was respectively 34.3% (95% CI: 17.8 to 47.5) 
for all ages; 34.7% (95% CI: 16 to 49.3) for those ≥ 18 
year of age and 25.2% (95% CI:-23.3, 54.7) for those < 18 
years. Further breakdown by age is shown in Table 4.
Vaccine effectiveness against influenza A virus 
infection
The adjusted overall VE against influenza A was 29.9% 
(95% CI: 10.5 to 45.1), very similar to the estimate seen 
specifically for A(H3N2) of 29.3% (95% CI: 8.6, 45.3) 
(Table 3) reflecting the dominance of A(H3N2).
The VE for A(H3N2) for the period October 2014 to 
January 2015 was 23.6% (95% CI: −2.9 to 43.2) com-
pared with 47.8% (95% CI: 10 to 69.7) for the period 
February to April 2015. VE for A(H3N2) for those vac-
cinated within three months of onset of illness was 
24.6% (95% CI: −2.7 to 44.6) compared with 34.4% 
(95% CI: 3.5 to 55.4) for those vaccinated more than 
three months before onset of illness.
For those aged 18 years and over, the influenza A VE 
was 30.4% (95% CI: 8.4 to 47.2) and for A(H3N2), it 
was 29.4% (95% CI: 5.8 to 47.1) (Table 4). The results 
were very similar for 18–44, 45–64 and ≥65 year olds, 
although with broader CIs for both influenza A and for 
A(H3N2). The VE against influenza A in the specific inac-
tivated influenza vaccine (IIV) target groups (aged ≥ 65 
or in a clinical risk group) was 34.8% (95% CI: 3.1 to 
56.2), with a similar result for A(H3N2). Although the 
VE showed some variability across the various surveil-
lance schemes, this difference was not significant.
For those aged under 18 years, the influenza A VE was 
17.5% (95% CI: −41.1 to 51.7) and for A(H3N2) 19.1% 
(95% CI: −44.1 to 54.6) (Table 5). There was no evidence 
of a significant difference in effectiveness in pilot and 
non-pilot areas. The estimate for vaccines administered 
by injection (VE = −69.4% (95% CI: −409.3 to 43.7%) 
was non-significantly lower than for vaccine adminis-
tered intranasally (VE = 31.2% (95% CI: −29.5 to 63.4). 
The estimates were very similar for A(H3N2) compared 
with those for influenza A overall. The results were also 
Table 5
Adjusted vaccine effectiveness estimates for influenza by age, type of vaccine and pilot area in < 18 year olds, United 
Kingdom, October 2014 to April 2015 (n = 701)
Factor Level Adjusted VEa% (95% CI) by type
A A(H3N2) B
Age
2,3,4 years 58.5 (−31.4 to 86.9) 69.2 (−30.9 to 92.7) 100 (−82.5 to 100)b
2,3,4 years intranasal 52.5 (−54.3 to 85.4) 65.7 (−50.1 to 92.1) 100 (−112.8 to 100)b
< 18 years intranasal 31.2 (−29.5 to 63.4) 35.0 (−29.9 to 67.5) 100 (17 to 100)b
< 18 years injection −69.4 (−409.3 to 43.7) −73.2 (−456.9 to 46.2) −123.7 (−1,343 to 65.3)
< 18 17.5 (−41.1 to 51.7) 19.1(−44.1 to 54.6) 59.4(−48.1 to 88.8)
Pilot area
Non-pilot 38.1 (−64.7 to 76.7) 37.9 (−77.6 to 78.3) 50 (−205.4 to 91.8)
Pilot 5.9 (−82 to 51.4) 5.4 (−92.4 to 53.4) 76.9 (−99.4 to 97.3)
CI: confidence interval;; RCGP: Royal College of General Practitioners Royal College of General Practitioners Research and Surveillance Centre; 
SMN Specialist Microbiology Network; VE: vaccine effectiveness.
a Adjusted for age group, sex, month, pilot area and surveillance scheme.
b Unadjusted Cornfield 95% confidence interval.
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similar for the sub-analysis in 2–4 year olds, with more 
uncertainty.
A regression analysis of the viral load (Ct values) in the 
A(H3N2) unvaccinated (n = 227) and vaccinated (n = 73) 
laboratory-confirmed cases received through the RCGP 
sentinel scheme in England, taking into account the 
number of days between onset and swab, found no 
statistically significant difference (p = 0.266) between 
the two groups. The mean difference in Ct values (not 
vaccinated – vaccinated) was −0.668 (95% CI: −1.848 
to 0.512).
Vaccine effectiveness against influenza B virus 
infection
The adjusted overall VE against influenza B was 46.3% 
(95% CI: 13.9 to 66.35 (Table 3). The VE for influenza B 
for those aged 18 and over was 43.6% (95% CI: 5.5 to 
66.3), with similar results for the 18–44 and 45–64 age 
groups, although with broader confidence intervals.
The VE against influenza B in the vaccine target group 
(aged ≥ 65 or in a risk group) was 15.5% (95% CI: −107.6 
to 65.6). Influenza B VE also showed some variability 
across the schemes although this difference was not 
significant (Table 4).
VE for those aged under 18 years of age for influenza B 
was 59.4% (95% CI: −48.1 to 88.8), with the estimate 
for vaccine administered by injection (VE = −123.7% 
(95% CI: −1,343 to 65.3) lower, but not statistically sig-
nificant, compared with that for vaccine administered 
intranasally, which did show evidence of significant 
protection (VE = 100%, 95% CI: 17 to 100.0). The results 
were similar for the sub-analysis in 2–4 year olds.
A sensitivity analysis for influenza A and B including 
all discarded samples (n = 922) due to late sampling 
(more than seven days after onset) did not lead to large 
changes in these point estimates, but slightly narrowed 
confidence intervals (data not shown).
Discussion
This study presents the end of season VE results for the 
2014/15 season, when the UK experienced circulation 
of both a drifted influenza A(H3N2) strain, followed by 
a drifted influenza B strain. This occurred in a season 
with a newly introduced universal paediatric influenza 
vaccination programme with a recently licensed live 
attenuated influenza vaccine. Our analysis finds that 
influenza A(H3N2) VE, unlike that for influenza B, was 
low, though nonetheless effective, in key target groups. 
Influenza B effectiveness was preserved despite the 
apparent drift of the main circulating B strains from the 
associated vaccine strain. Finally, there was a sugges-
tion of effectiveness of LAIV in children against both 
influenza A and B.
The UK, as several other northern hemisphere coun-
tries, experienced circulation of an antigenically and 
genetically drifted A(H3N2) strain, which was asso-
ciated in particular with impact in the elderly, with 
levels of excess mortality higher than seen in the last 
substantial A(H3N2) season in 2008/09 [1,4]. The VE 
results presented in this paper indicate an overall 
effectiveness against medically attended laboratory-
confirmed influenza in primary care of ca 30%, which 
although lower than would be anticipated for a well- or 
moderately matched influenza vaccine, still indicates 
some clinically beneficial protection against the drifted 
strain. The age-specific estimates in the over 18 year 
olds (which will represent the effect of IIV) were broadly 
similar in the elderly and clinical at-risk groups. These 
end-of-season VE results, although low, are non-signif-
icantly higher than the mid-season point-estimate (of 
3.4%) undertaken in January 2015 had suggested [5], 
and which had mirrored the findings elsewhere, in par-
ticular in Canada and North America [14,15]. Previous 
interim, mid-season estimates have usually provided 
a good indication of the final end-of-season measure, 
albeit with more uncertainty as they are based on a 
smaller sample size. The apparent difference this sea-
son could be due to a range of potential factors. The 
higher overall VE will be partially explained by the 
higher VE against influenza B which circulated later in 
the season, though this will not explain the difference 
in the point estimate for influenza A. One explanation 
for this observation might be changes in the circulation 
of A(H3N2) genetic sub-groups over the season, how-
ever there was no significant change in the monthly pro-
portion of A(H3N2) for genetic groups 3C.3 and 3C.2a 
(data not shown) over the season, and random varia-
tion seems to provide the most likely explanation for 
our observed non-significant difference between VE at 
the middle and the end of the season. The mid-season 
estimates, with all their uncertainty, did nonetheless 
provide an early indication of lower effectiveness of the 
A(H3N2) component of the seasonal influenza vaccine 
and was important for public health action purposes to 
highlight the value of other interventions, in particular 
use of antivirals for treatment and prophylaxis.
Influenza A(H3N2) is generally considered to be asso-
ciated with more severe disease in the elderly and 
the lower VE seen this season is likely to have been 
a contributory factor to the relatively severe impact of 
influenza observed this year. The last intense H3N2 
season was in 2008/09, where even in a season 
with a moderately matched H3N2 vaccine component 
with high coverage in the elderly, significant levels of 
excess mortality in the > 65 year olds was still seen [16]. 
These observations highlight the limitations of the tra-
ditional, selective influenza vaccination policy of tar-
geting groups at higher risk of severe disease such 
as the elderly and were part of the rationale for the 
introduction of the live attenuated influenza vaccina-
tion programme for healthy children, which attempts to 
not only provide direct protection to the children them-
selves, but to also reduce transmission of influenza 
and thus provide indirect protection to the rest of the 
population.
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The main circulating influenza B strain this season 
was also drifted, with the dominant circulating B 
strain being of the B/Yamagata/16/88 lineage, but 
with reduced antigenicity to the 2014/15 northern 
hemisphere B/Yamagata-lineage vaccine virus, B/
Massachusetts/2/2012 [1]. However, despite this viro-
logical finding, the overall influenza B VE was still 
moderately high at almost 50% effectiveness against 
the main circulating B strains and highlights the impor-
tance of observational VE studies to fully understand 
the clinical impact of drift when it occurs, and also the 
fact that tri/quadrivalent influenza vaccines provide 
potential protection against all these seasonal influ-
enza types and subtypes. It is also important to note 
that the B viruses circulating this season are also anti-
genically similar to B/Phuket/3073/2013, the influenza 
B/Yamagata lineage virus selected for 2015/16 north-
ern hemisphere influenza vaccines [17].
It is important to note that several of the sub-analy-
ses, particularly stratifying VE by age, pilot area and 
scheme, result in estimates with lower precision. There 
were no significant differences in VE by these co-vari-
ates although the point estimates for VE against influ-
enza A were different. These differences are likely to 
be chance fluctuations due to small numbers and high-
light the need for large numbers of swabs to improve 
the power of such subgroup analyses.
Despite these limitations, for the under 18 year olds, our 
results provide evidence of significant effectiveness 
for the live attenuated intranasally administered vac-
cine for influenza B, albeit based on limited numbers. 
The LAIV VE estimate for influenza A indicated non-sig-
nificant protection and is congruent with the published 
literature indicating that LAIV can provide cross-pro-
tection against drifted strains [18-20]. Although the US 
[18], has dropped its preferential recommendation for 
the use of LAIV in children, the UK findings are particu-
larly encouraging for this season, with the circulation 
of both A(H3N2) and B drifted strains and support the 
rationale for the introduction of the universal paedi-
atric programme. Further work is underway to exam-
ine the population impact of the childhood influenza 
vaccine programme by comparing pilot and non-pilot 
school age programme areas in England and across the 
UK to investigate in particular the presence and size of 
any indirect effects of the programme.
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